Login / Signup

Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.

Vasileios-Periklis StamatellosSpyridon SiafisGeorgios Papazisis
Published in: British journal of clinical pharmacology (2021)
No safety signal for increased cancer risk was detected among the approved DMTs. A potential safety signal detected in the sensitivity analysis concerning Interferon beta-1a and Alemtuzumab requires further evaluation with more robust evidence.
Keyphrases
  • drug administration
  • adverse drug
  • multiple sclerosis
  • papillary thyroid
  • human health
  • dendritic cells
  • squamous cell
  • emergency department
  • lymph node metastasis
  • drug induced